Organization (Hospital)
Ascension Health
ClinicalTrials.gov lists Ascension Health as lead sponsor of 22 trials. It has 5 active development programs and 12 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Ascension Health: 22 lead-sponsored trials and 0 legal-entity registrations.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (94)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 5 |
| Heart Failure | 4 |
| Inflammation | 4 |
| Hypoxia | 3 |
| Obesity | 3 |
Showing 5 of 94 disease areas.
Trials by start year as sponsor or collaborator (17)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 4 |
| 2022 | 2 |
| 2021 | 4 |
| 2020 | 1 |
| 2019 | 3 |
| 2018 | 1 |
| 2017 | 1 |
Showing 10 of 17 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (5)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Tranexamic Acid | Hemorrhage | Phase 2/3 | 1 |
| Tranexamic Acid | Postoperative Hemorrhage | Phase 2/3 | 1 |
| HAT | Inflammation | Phase 1/2 | 1 |
| HAT | Sepsis | Phase 1/2 | 1 |
| Petrolatum Ointment | Dermatitis, Seborrheic | Not reported | 1 |
Approved assets (12)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Lisinopril | 1 |
| Omeprazole | 1 |
| Nu-Lytely | 1 |
| Acetaminophen | 1 |
| DEXAMETHASONE | 1 |
Showing 5 of 12 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 14% hit target (n=7) | 57% on time (n=7) |
Journals published in (99)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Circulation | 8 |
| Journal of the American College of Cardiology | 5 |
| Pediatrics | 5 |
| The Journal of pediatrics | 5 |
| The Journal of thoracic and cardiovascular surgery | 5 |
Showing 5 of 99 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 3 | 0 | 2013-04-23 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2019-10-31 |
Organization relationships (46)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of California System | Co sponsors trial with | 2 |
| UPMC Health System | Co sponsors trial with | 1 |
| University of Alberta | Co sponsors trial with | 1 |
| Cincinnati Children's Hospital Medical Center | Co sponsors trial with | 1 |
| Roche (Switzerland) | Co sponsors trial with | 1 |
Showing 5 of 46 relationships.
Latest dated events (69)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-05-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-08-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 69 events.
CLIA clinical laboratory certificates (2)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| ASCENSION | Certificate for PPM procedures | Terminated |
| ST JOHN PROVIDENCE HEALTH SYSTEM | Certificate of waiver | Terminated |
Biomarker capability evidence (17)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| BTBD8 | Trial collaborator | Named in trial inclusion criteria |
| G6PD | Trial sponsor | Named in trial inclusion criteria |
| H6PD | Trial sponsor | Named in trial inclusion criteria |
| PDC | Trial sponsor | Named in trial inclusion criteria |
| ACE | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 17 evidence rows.
Biomarkers this organization publishes on (19)
Shown in this order: most publications first.
Showing 5 of 19 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.